Nuvalent (NUVL) Interest & Investment Income (2022 - 2026)
Nuvalent (NUVL) reported Interest & Investment Income of $12.9 million for Q1 2026, up 8.71% on a YoY basis from $11.8 million in Q1 2025, and up 11.54% quarter-over-quarter from $11.5 million in Q4 2025.
Nuvalent (NUVL) Interest & Investment Income (2022 - 2026) Analysis & Trends
Nuvalent has reported Interest & Investment Income for 5 years, with the latest figure at $12.9 million in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income rose 8.71% year-over-year to $12.9 million; the trailing twelve-month figure through Mar 2026 stood at $45.7 million (up 9.36% YoY), and the FY2025 full-year result was $44.7 million, up 16.5% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $12.9 million, up from $11.5 million in the prior quarter.
- The five-year high for Interest & Investment Income was $13.1 million in Q4 2024, with the low at $139000.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $7.3 million across 5 years, with a median of $8.2 million in 2023.
- Annual changes were most pronounced in 2023 — Interest & Investment Income soared 3510.07% — and 2025, when it fell 11.97%.
- Nuvalent's Interest & Investment Income stood at $3.2 million in 2022, then surged by 156.82% to $8.2 million in 2023, then soared by 60.34% to $13.1 million in 2024, then slipped by 11.97% to $11.5 million in 2025, then rose by 11.54% to $12.9 million in 2026.
- The last three Interest & Investment Income figures came in at $12.9 million (Q1 2026), $11.5 million (Q4 2025), and $10.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 597,319.59 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -14.79 Mn |
| 10 | Nuvalent | 9.70 Bn | 9.70 Bn | - | 12.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.87 Mn |
| Dec 31, 2025 | 11.54 Mn |
| Sep 30, 2025 | 10.20 Mn |
| Jun 30, 2025 | 11.10 Mn |
| Mar 31, 2025 | 11.84 Mn |
| Dec 31, 2024 | 13.10 Mn |
| Sep 30, 2024 | 8.70 Mn |
| Jun 30, 2024 | 8.15 Mn |
| Mar 31, 2024 | 8.50 Mn |
| Dec 31, 2023 | 8.17 Mn |
| Sep 30, 2023 | 5.14 Mn |
| Jun 30, 2023 | 4.97 Mn |
| Mar 31, 2023 | 5.02 Mn |
| Dec 31, 2022 | 3.18 Mn |
| Sep 30, 2022 | 672,000.00 |
| Jun 30, 2022 | 267,000.00 |
| Mar 31, 2022 | 139,000.00 |